Home › Products › Oncology › Kryxana 200mg Tablet
Kryxana 200mg Tablet
Salt Composition: RIBOCICLIB
- Manufacturer: NOVARTIS INDIA LTD
- Pack Size: 21 TABLET(s) IN A STRIP
- Dosage Form: TABLET
- Strength: 200MG
- Prescription Required
- Cold Chain
- Prepaid Only. Non-Returnable.
- Storage: Kryxana 200mg Tablet tablets should be stored at room temperature between 20°C and 25°C (68°F and 77°F). It should be kept dry and protected from light and moisture. The tablets should be kept in the original packaging with the cap tightly closed. Keep it out of reach from children and pets. It is important to get the dose at the scheduled time. If you missed the schedule, contact your doctor and ask them about how to reschedule the dose.
₹20900.00₹24356.00
Inclusive of all taxes
Product Introduction
Kryxana 200mg Tablet contains Ribociclib Succinate, a cyclin-dependent kinase (CDK) 4/6 inhibitor that helps slow the growth and spread of certain breast cancer cells. It is primarily prescribed for adults with hormone receptor (HR)-positive, HER2-negative breast cancer, including advanced or metastatic disease and early-stage breast cancer with a high risk of recurrence. By blocking the CDK4/6 proteins responsible for cancer cell division, Kryxana 200mg Tablet helps delay disease progression and reduce the risk of cancer returning.
This medicine should be taken only under the supervision of an experienced oncologist. Avoid using Kryxana 200mg Tablet if you are allergic to ribociclib, peanuts, soya, or any of its other ingredients. Before starting treatment, inform your doctor if you have a history of liver disease, kidney problems, heart disorders, or conditions that may affect the QT interval. Routine monitoring, including blood tests, liver function tests, and electrocardiograms (ECGs), is necessary throughout treatment to ensure safety and effectiveness. Kryxana 200mg Tablet should not be used during pregnancy or while breastfeeding, as it may harm the baby. Women of childbearing potential should use effective contraception during treatment and continue it for at least 3 weeks after the final dose.
Uses
Advanced or metastatic breast cancer Advanced or metastatic endometrial cancer
How it works
Ribociclib works by blocking specific proteins (CDK4 and CDK6) that help cancer cells grow and divide. By inhibiting these proteins, the drug prevents tumor cells from multiplying, slowing down disease progression in both early and advanced breast cancer. Taken alongside hormonal therapies, it boosts their effectiveness and reduces the risk of cancer returning after surgery. This dual action improves patient outcomes with manageable side effects.
How to Use
The recommended dose is 600â¯mg daily, which equates to three 200â¯mg film-coated tablets, taken orally once a day for 21 consecutive days followed by a 7-day break, completing a 28-day cycle. Tablets should be swallowed whole with or without food, preferably at the same time each morning to maintain consistent levels. Dose may be reduced to 400â¯mg or 200â¯mg in case of intolerance or drug interactions.
Side Effects
Side Effects: Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious : QT interval prolongation Hepatobiliary toxicity (liver enzyme elevations) Pneumonitis/interstitial lung disease Severe neutropenia (low white blood cell counts) Common : Neutropenia Nausea, diarrhea, constipation Vomiting Fatigue, headache Hair thinning or loss Rash, cough
References
- Novartis Pharmaceuticals UK Ltd, Electronic medicines compendium (emc), [Revised on 18 Jan 2023], [Accessed on 29th March 2023], https://www.medicines.org.uk/emc/product/8110/smpc
- Novartis Pharmaceuticals, U. S National Library of Medicine, [ Revised on Dec 2022] [Accessed on 28th March 2023], https://clinicaltrials.gov/ct2/show/NCT03701334
- Novartis Pharmaceuticals Corporation, U.S. Food and Drug Administration. Highlights of Prescribing Information: Ribociclib. [Last revised 2017], [Accessed on 29th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
- Vincent T. DeVita Jr., Theodore S. Lawrence, Steven A. Rosenberg, Cancer Chemotherapy: Principles and Practice Authors, 10th Edition, 2020, 993-994
Safety Advice
Pregnancy: unsafe Kryxana 200mg Tablet is unsafe for pregnant women as it may cause foetal harm if taken during pregnancy. So it is recommended to avoid it during pregnancy.
Lungs: Consult your doctor Kryxana 200mg Tablet has been associated with some lung-related side effects, although these are relatively uncommon. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Kryxana 200 mg Tablet is unsafe for use during breastfeeding. Because of the potential risk to the infant, breastfeeding is not recommended during treatment.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.